Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

 
• By Joseph Haas
  
Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip